Summary
This study will evaluate a new form of targeted therapy, called BG-C9074, both on its own and with immunotherapy called tislelizumab, to see how safe it is, how the body processes it, and if it helps treat advanced tumours.
BG-C9074 and Tislelizumab will be administered to participants via IV infusion.
The study has multiple parts.
In Phase 1a Part A (Monotherapy Dose Escalation), BG-C9074 will be given by itself in escalating doses.
During Phase 1a Part B (Monotherapy Safety Expansion), the safety and effectiveness of BG-C9074 will be further investigated by administering it at the dose levels determined to be safe and tolerable in Part A.
In Phase 1a Part C (Combination Therapy Dose Escalation), participants will receive BG-C9074 plus Tislelizumab at the recommended dose for expansion (RDFE).
Phase 1b (Monotherapy Dose Expansion) will begin once the BG-C9074 monotherapy RDFE and dosing schedule have been determined from Parts A and B in Phase 1a.
Participants will receive the treatments until their disease gets worse, they experience unacceptable side effects, withdraw from the study, or meet another reason for stopping. Participants may receive the treatments for up to two years.